Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG.

Cancer. 2018 May 3. doi: 10.1002/cncr.31517. [Epub ahead of print] Review.

PMID:
29723407
2.

The risk of carotid stenosis in head and neck cancer patients after radiation therapy.

Carpenter DJ, Mowery YM, Broadwater G, Rodrigues A, Wisdom AJ, Dorth JA, Patel PR, Shortell CK, Clough R, Brizel DM.

Oral Oncol. 2018 May;80:9-15. doi: 10.1016/j.oraloncology.2018.02.021. Epub 2018 Mar 14.

PMID:
29706194
3.

Characterizing the Potency and Impact of Carbon Ion Therapy in a Primary Mouse Model of Soft Tissue Sarcoma.

Brownstein JM, Wisdom AJ, Castle KD, Mowery YM, Guida P, Lee CL, Tommasino F, Tessa C, Scifoni E, Gao J, Luo L, Campos LDS, Ma Y, Williams N, Jung SH, Durante M, Kirsch DG.

Mol Cancer Ther. 2018 Apr;17(4):858-868. doi: 10.1158/1535-7163.MCT-17-0965. Epub 2018 Feb 7.

PMID:
29437879
4.

Interventions Targeting the Prescribing and Monitoring of Vancomycin for Hospitalized Patients: A Systematic Review Protocol.

Phillips CJ, Wisdom AJ, McKinnon RA, Woodman RJ, Gordon DL.

Infect Dis Ther. 2017 Dec;6(4):557-563. doi: 10.1007/s40121-017-0177-7. Epub 2017 Oct 27. Review.

5.

Human Adipose-Derived Stem Cells Labeled with Plasmonic Gold Nanostars for Cellular Tracking and Photothermal Cancer Cell Ablation.

Shammas RL, Fales AM, Crawford BM, Wisdom AJ, Devi GR, Brown DA, Vo-Dinh T, Hollenbeck ST.

Plast Reconstr Surg. 2017 Apr;139(4):900e-910e. doi: 10.1097/PRS.0000000000003187.

6.

The impact of a pilot continuing professional development module on hospital pharmacists' preparedness to provide contemporary advice on the clinical use of vancomycin.

Phillips CJ, Wisdom AJ, Eaton VS, Woodman RJ, McKinnon RA.

Springerplus. 2016 Mar 15;5:331. doi: 10.1186/s40064-016-1966-2. eCollection 2016.

7.

Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons.

Spence RD, Wisdom AJ, Cao Y, Hill HM, Mongerson CR, Stapornkul B, Itoh N, Sofroniew MV, Voskuhl RR.

J Neurosci. 2013 Jun 26;33(26):10924-33. doi: 10.1523/JNEUROSCI.0886-13.2013.

8.

Estrogen receptor-β ligand treatment after disease onset is neuroprotective in the multiple sclerosis model.

Wisdom AJ, Cao Y, Itoh N, Spence RD, Voskuhl RR.

J Neurosci Res. 2013 Jul;91(7):901-8. doi: 10.1002/jnr.23219. Epub 2013 Apr 30.

9.

Neuroprotection mediated through estrogen receptor-alpha in astrocytes.

Spence RD, Hamby ME, Umeda E, Itoh N, Du S, Wisdom AJ, Cao Y, Bondar G, Lam J, Ao Y, Sandoval F, Suriany S, Sofroniew MV, Voskuhl RR.

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8867-72. doi: 10.1073/pnas.1103833108. Epub 2011 May 9.

Supplemental Content

Loading ...
Support Center